194 related articles for article (PubMed ID: 36638187)
1. A differential proteomics study of cerebrospinal fluid from individuals with Niemann-Pick disease, Type C1.
Li W; Pergande MR; Crutchfield CA; Searle BC; Backlund PS; Picache JA; Burkert K; Yanjanin-Farhat NM; Blank PS; Toth CL; Wassif CA; Porter FD; Cologna SM
Proteomics; 2023 Jun; 23(11):e2200378. PubMed ID: 36638187
[TBL] [Abstract][Full Text] [Related]
2. Quantitative proteomic analysis of Niemann-Pick disease, type C1 cerebellum identifies protein biomarkers and provides pathological insight.
Cologna SM; Jiang XS; Backlund PS; Cluzeau CV; Dail MK; Yanjanin NM; Siebel S; Toth CL; Jun HS; Wassif CA; Yergey AL; Porter FD
PLoS One; 2012; 7(10):e47845. PubMed ID: 23144710
[TBL] [Abstract][Full Text] [Related]
3. Quantitative, Label-Free Proteomics in the Symptomatic Niemann-Pick, Type C1 Mouse Model Using Standard Flow Liquid Chromatography and Thermal Focusing Electrospray Ionization.
Pergande MR; Nguyen TTA; Haney-Ball C; Davidson CD; Cologna SM
Proteomics; 2019 May; 19(9):e1800432. PubMed ID: 30888112
[TBL] [Abstract][Full Text] [Related]
4. Altered transition metal homeostasis in Niemann-Pick disease, type C1.
Hung YH; Faux NG; Killilea DW; Yanjanin N; Firnkes S; Volitakis I; Ganio G; Walterfang M; Hastings C; Porter FD; Ory DS; Bush AI
Metallomics; 2014 Mar; 6(3):542-53. PubMed ID: 24343124
[TBL] [Abstract][Full Text] [Related]
5. Elevated cerebrospinal fluid ubiquitin C-terminal hydrolase-L1 levels correlate with phenotypic severity and therapeutic response in Niemann-Pick disease, type C1.
Cawley NX; Giddens S; Farhat NM; Luke RA; Scott KEJ; Mohamed HO; Dang Do A; Berry-Kravis E; Cologna SM; Liu F; Porter FD
Mol Genet Metab; 2023 Nov; 140(3):107656. PubMed ID: 37517328
[TBL] [Abstract][Full Text] [Related]
6. Human and mouse neuroinflammation markers in Niemann-Pick disease, type C1.
Cologna SM; Cluzeau CV; Yanjanin NM; Blank PS; Dail MK; Siebel S; Toth CL; Wassif CA; Lieberman AP; Porter FD
J Inherit Metab Dis; 2014 Jan; 37(1):83-92. PubMed ID: 23653225
[TBL] [Abstract][Full Text] [Related]
7. Intravenous 2-hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: Results of a phase 1 trial.
Hastings C; Liu B; Hurst B; Cox GF; Hrynkow S
Mol Genet Metab; 2022 Dec; 137(4):309-319. PubMed ID: 36279795
[TBL] [Abstract][Full Text] [Related]
8. Neurofilament light chain in cerebrospinal fluid as a novel biomarker in evaluating both clinical severity and therapeutic response in Niemann-Pick disease type C1.
Agrawal N; Farhat NY; Sinaii N; Do AD; Xiao C; Berry-Kravis E; Bianconi S; Masvekar R; Bielekova B; Solomon B; Porter FD
Genet Med; 2023 Mar; 25(3):100349. PubMed ID: 36470574
[TBL] [Abstract][Full Text] [Related]
9. Standard-flow LC and thermal focusing ESI elucidates altered liver proteins in late stage Niemann-Pick, type C1 disease.
Pergande MR; Zarate E; Haney-Ball C; Davidson CD; Scesa G; Givogri MI; Bongarzone ER; Cologna SM
Bioanalysis; 2019 Jun; 11(11):1067-1083. PubMed ID: 31251104
[No Abstract] [Full Text] [Related]
10. Beneficial effects of primidone in Niemann-Pick disease type C (NPC)-model cells and mice: Reduction of unesterified cholesterol levels in cells and extension of lifespan in mice.
Ashikawa H; Mogi H; Honda T; Nakamura H; Murayama T
Eur J Pharmacol; 2021 Apr; 896():173907. PubMed ID: 33503462
[TBL] [Abstract][Full Text] [Related]
11. Different Trafficking Phenotypes of Niemann-Pick C1 Gene Mutations Correlate with Various Alterations in Lipid Storage, Membrane Composition and Miglustat Amenability.
Brogden G; Shammas H; Walters F; Maalouf K; Das AM; Naim HY; Rizk S
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32204338
[TBL] [Abstract][Full Text] [Related]
12. Differential Effects of 2-Hydroxypropyl-Cyclodextrins on Lipid Accumulation in
Hoque S; Kondo Y; Sakata N; Yamada Y; Fukaura M; Higashi T; Motoyama K; Arima H; Higaki K; Hayashi A; Komiya T; Ishitsuka Y; Irie T
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019132
[TBL] [Abstract][Full Text] [Related]
13. Improved neuroprotection using miglustat, curcumin and ibuprofen as a triple combination therapy in Niemann-Pick disease type C1 mice.
Williams IM; Wallom KL; Smith DA; Al Eisa N; Smith C; Platt FM
Neurobiol Dis; 2014 Jul; 67():9-17. PubMed ID: 24631719
[TBL] [Abstract][Full Text] [Related]
14. Molecular profile and peripheral markers of neurodegeneration in patients with Niemann-Pick type C: Decrease in Plasminogen Activator Inhibitor type 1 and Platelet-Derived Growth Factor type AA.
Hammerschmidt TG; Encarnação M; Lamberty Faverzani J; de Fátima Lopes F; Poswar de Oliveira F; Fischinger Moura de Sousa C; Ribeiro I; Alves S; Giugliani R; Regla Vargas C
Arch Biochem Biophys; 2023 Feb; 735():109510. PubMed ID: 36608914
[TBL] [Abstract][Full Text] [Related]
15. Differential Proteomics Reveals miR-155 as a Novel Indicator of Liver and Spleen Pathology in the Symptomatic Niemann-Pick Disease, Type C1 Mouse Model.
Pergande MR; Cougnoux A; Rathnayake RAC; Porter FD; Cologna SM
Molecules; 2019 Mar; 24(5):. PubMed ID: 30870990
[TBL] [Abstract][Full Text] [Related]
16. Reduction of glutamate neurotoxicity: A novel therapeutic approach for Niemann-Pick disease, type C1.
Cougnoux A; Yerger JC; Fellmeth M; Serra-Vinardell J; Navid F; Wassif CA; Cawley NX; Porter FD
Mol Genet Metab; 2021 Dec; 134(4):330-336. PubMed ID: 34802899
[TBL] [Abstract][Full Text] [Related]
17. The potential of histone deacetylase inhibitors in Niemann - Pick type C disease.
Maceyka M; Milstien S; Spiegel S
FEBS J; 2013 Dec; 280(24):6367-72. PubMed ID: 23992240
[TBL] [Abstract][Full Text] [Related]
18. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium.
Lloyd-Evans E; Morgan AJ; He X; Smith DA; Elliot-Smith E; Sillence DJ; Churchill GC; Schuchman EH; Galione A; Platt FM
Nat Med; 2008 Nov; 14(11):1247-55. PubMed ID: 18953351
[TBL] [Abstract][Full Text] [Related]
19. Main Olfactory and Vomeronasal Epithelium Are Differently Affected in Niemann-Pick Disease Type C1.
Witt M; Thiemer R; Meyer A; Schmitt O; Wree A
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30424529
[TBL] [Abstract][Full Text] [Related]
20. Assessment of FDA-Approved Drugs as a Therapeutic Approach for Niemann-Pick Disease Type C1 Using Patient-Specific iPSC-Based Model Systems.
Völkner C; Pantoom S; Liedtke M; Lukas J; Hermann A; Frech MJ
Cells; 2022 Jan; 11(3):. PubMed ID: 35159129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
